Japanese regulators are expected to give quick approval for marketing Chugai Pharmaceutical Co.'s Avastin, a cancer treatment produced by Genentech. The government's focus on getting cancer drugs approved and apparent investor interest in Chugai is seen as part of a trend of an expanding market for cancer drugs in Japan.

Related Summaries